RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430

RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Amgen (NASDAQ: AMGN) and raised the price target from $400 to $430. This adjustment reflects a positive outlook on the company's performance.